Predictorsa | Patients infected with the concordant pulsotypes (n = 56) | Patients infected with the discordant pulsotypes (n = 41) | Univariable OR (95% CI) | P | Multivariablec OR (95% CI) | P |
---|---|---|---|---|---|---|
Demographics | ||||||
 Age (y) | 70.9 (60.0–78.6) | 65.6 (55.2–77.4) | 1.01 (0.98–1.04) | 0.56 |  |  |
 Gender | 30 (53.6) | 18 (43.9) | 1.47 (0.66–3.31) | 0.35 |  |  |
Comorbid conditions at identification | ||||||
 Charlson score | 4.0 (2.5–5.0) | 4.0 (3.0–6.0) | 0.95 (0.81–1.12) | 0.55 |  |  |
 Myocardial infarction | 3 (5.4) | 1 (2.4) | 2.26 (0.23–22.59) | 0.46 |  |  |
 Congestive heart failure | 4 (7.1) | 6 (14.6) | 0.45 (0.12–1.71) | 0.23 |  |  |
 Peripheral occlusive arterial disease | 1 (1.8) | 0 (0) | NA | NA |  |  |
 Cerebrovascular diseases | 6 (10.7) | 10 (24.4) | 0.37 (0.12–1.13) | 0.08 | 0.22 (0.06–0.78) | 0.02 |
 Hemiplegia | 3 (5.4) | 3 (7.3) | 0.72 (0.14–3.75) | 0.69 |  |  |
 Dementia | 6 (10.7) | 0 (0) | NA | NA |  |  |
 Chronic pulmonary disease | 4 (7.1) | 3 (7.3) | 0.97 (0.21–4.61) | 0.97 |  |  |
 Connective tissue disease | 2 (3.6) | 1 (2.4) | 1.48 (0.13–16.91) | 0.75 |  |  |
 Peptic ulcer disease | 11 (19.6) | 8 (19.5) | 1.01 (0.37–2.78) | 0.99 |  |  |
 Mild liver diseases | 6 (10.7) | 8 (19.5) | 0.50 (0.16–1.56) | 0.23 |  |  |
 Moderate-to-severe liver diseases | 5 (8.9) | 2 (4.9) | 1.91 (0.35–10.38) | 0.44 |  |  |
 Moderate-to-severe renal diseases | 22 (39.3) | 17 (41.5) | 0.91 (0.40–2.08) | 0.83 |  |  |
 Diabetes mellitus without end organ damage | 21 (37.5) | 14 (34.2) | 1.16 (0.50–2.69) | 0.73 |  |  |
 Diabetes mellitus with end organ damage | 3 (5.4) | 4 (9.8) | 0.52 (0.11–2.48) | 0.41 |  |  |
 Solid tumor without metastases | 11 (19.6) | 10 (24.4) | 0.76 (0.29–2.00) | 0.58 |  |  |
 Metastatic solid tumor | 4 (7.1) | 3 (7.3) | 0.97 (0.21–4.61) | 0.97 |  |  |
 Leukemia | 8 (14.3) | 9 (22.0) | 0.59 (0.21–1.70) | 0.33 |  |  |
 Lymphoma | 2 (3.6) | 2 (4.9) | 0.72 (0.10–5.35) | 0.75 |  |  |
 Acquired immunodeficiency syndrome | 1 (1.8) | 0 (0) | NA | NA |  |  |
Healthcare factors within 30 days before EOF | ||||||
 Receipt of solid organ transplantation | 0 (0) | 0 (0) | NA | NA |  |  |
 Receipt of hematopoietic stem cell transplantation | 1 (1.8) | 2 (4.9) | 0.35 (0.03–4.05) | 0.40 |  |  |
 New receipt of hemodialysis | 10 (17.9) | 5 (12.2) | 1.57 (0.49–4.99) | 0.45 |  |  |
 ICU admission | 45 (80.4) | 20 (48.8) | 4.30 (1.75–10.56) | 0.001 | 3.74 (1.38–10.13) | 0.009 |
 GI intervention | 9 (16.1) | 4 (9.8) | 1.77 (0.51–6.21) | 0.37 |  |  |
 Steroid use | 26 (46.4) | 24 (58.5) | 0.61 (0.27–1.38) | 0.24 |  |  |
 Chemotherapy | 8 (14.3) | 10 (24.4) | 0.52 (0.18–1.45) | 0.21 |  |  |
 Parental hyperalimentation | 25 (44.6) | 15 (36.6) | 1.40 (0.61–3.19) | 0.42 |  |  |
 Neutropenia | 9 (16.1) | 5 (12.2) | 1.38 (0.43–4.47) | 0.59 |  |  |
 Mechanical ventilator | 34 (60.7) | 15 (36.6) | 2.68 (1.17–6.15) | 0.02 |  |  |
 Indwelling urinary catheter | 25 (44.6) | 13 (31.7) | 1.74 (0.75–4.03) | 0.20 |  |  |
 Central venous catheters | 51 (91.1) | 36 (87.8) | 1.42 (0.38–5.26) | 0.60 |  |  |
Antibiotics use within 30 days before EOF | ||||||
 Antipseudomonal penicillin | 12 (21.4) | 8 (19.5) | 1.13 (0.41–3.06) | 0.82 |  |  |
 Penicillins combined with β-lactamases inhibitors | 0 (0) | 2 (4.9) | NA | NA |  |  |
 First-generation cephalosporin | 0 (0) | 0 (0) | NA | NA |  |  |
 Second-generation cephalosporin | 4 (7.1) | 2 (4.9) | 1.50 (0.26–8.60) | 0.65 |  |  |
 Third-generation cephalosporin | 16 (28.6) | 16 (39.0) | 0.63 (0.27–1.47) | 0.28 |  |  |
 Fourth-generation cephalosporin | 18 (32.4) | 11 (26.8) | 1.29 (0.53–3.15) | 0.57 |  |  |
 Carbapenem | 24 (42.9) | 16 (39.0) | 1.17 (0.52–2.66) | 0.71 |  |  |
 Fluoroquinolone | 9 (16.1) | 18 (43.9) | 0.24 (0.10–0.63) | 0.003 | 0.35 (0.12–1.02) | 0.05 |
 Metronidazole | 4 (7.1) | 3 (7.3) | 0.97 (0.21–4.61) | 0.97 |  |  |
 Aminoglycoside | 6 (10.7) | 2 (4.9) | 2.34 (0.45–12.24) | 0.31 |  |  |
 Glycopeptide | 12 (21.4) | 17 (41.5) | 0.39 (0.16–0.94) | 0.04 |  |  |
 Tigecycline | 2 (3.6) | 1 (2.4) | 1.48 (0.13–16.91) | 0.75 |  |  |
 Daptomycin | 5 (8.9) | 3 (7.3) | 1.24 (0.28–5.52) | 0.78 |  |  |
 Linezolid | 8 (14.3) | 6 (14.6) | 0.97 (0.31–3.05) | 0.96 |  |  |
 SXT | 4 (7.1) | 5 (12.2) | 0.55 (0.14–2.21) | 0.40 |  |  |
 Othersb | 9 (16.1) | 10 (24.4) | 0.59 (0.22–1.63) | 0.31 |  |  |
Infection type | ||||||
 BSI vs. other types of infection | 24 (42.9) | 16 (39.0) | 1.17 (0.52–2.66) | 0.71 |  |  |
 Early infection | 36 (64.3) | 13 (31.7) | 3.88 (1.64–9.12) | 0.001 | 3.34 (1.25–8.91) | 0.02 |
 Common PFTs of colonization isolatesd | 18 (32.1) | 16 (39.2) | 0.74 (0.32–1.72) | 0.48 |  |  |